Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Leukemia Research
|
November 8, 2021
MYC overexpression is associated with an early disease progression from MDS to AML
David Gajzer, Constantine N Logothetis, David A Sallman, et al.
American Journal of Hematology
|
August 7, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
Somedeb Ball, Akriti G Jain, Najla Al Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Naval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Leukemia & Lymphoma
|
July 29, 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia
Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, et al.
Blood Advances
|
October 15, 2020
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Blood Cancer Discovery
|
February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Dimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2023
CML and the WHO: Why?
Ellin Berman, Neil P Shah, Michael Deninger, et al.
Blood Advances
|
February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia
Athalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Leukemia Research
|
November 8, 2021
MYC overexpression is associated with an early disease progression from MDS to AML
David Gajzer, Constantine N Logothetis, David A Sallman, et al.
American Journal of Hematology
|
August 7, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
Somedeb Ball, Akriti G Jain, Najla Al Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
Naval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Leukemia & Lymphoma
|
July 29, 2021
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia
Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, et al.
Blood Advances
|
October 15, 2020
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Blood Cancer Discovery
|
February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Dimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2023
CML and the WHO: Why?
Ellin Berman, Neil P Shah, Michael Deninger, et al.
Blood Advances
|
February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia
Athalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Page
of 9